Navigation Links
TNI BioTech, Inc. Announces Appointment of New CFO

BETHESDA, Md., Jan. 22, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB) today announced that Mr. Peter Aronstam has been appointed Chief Financial Officer.

Mr. Peter Aronstam is replacing Mr. Christopher Pearce , who will take over as the Chief Operating Officer. Mr. Pearce has extensive experience in corporate operations and will be available for assistance during the transition period. 

"Mr. Aronstam's broad-based experience as a finance professional in private and public companies gives him a solid platform for the job of Chief Financial Officer of TNI BioTech," commented Ms. Noreen Griffin , Chief Executive Officer. "We welcome Peter and look forward to working with him as part of the TNI BioTech management team."

"Mr. Pearce has done a tremendous job as Chief Financial Officer. He joined TNI BioTech nine months ago at its onset and has been a great asset to our operations throughout our period of growth and acquisition. I am pleased that Mr. Pearce will be available to assist TNI BioTech during the transition between CFOs, and will also assume the position as Chief Operating Officer. I also wish to thank him for his ongoing commitment to TNI BioTech." continued Ms. Griffin.

TNI BioTech, Inc. has made these personnel changes in connection with the retention and engagement of Liggett, Vogt & Webb P.A. This accounting firm has been retained to provide professionally audited financial statements for inclusion in a Form 10 filing with the Securities Exchange Commission in approximately 45 days. The Form 10 is required for TNI BioTech to up-list to a fully reporting company.

Mr. Peter Aronstam brings more than 30 years of experience in accounting, finance, banking, international trade, and law to TNI BioTech, Inc. His career is noted by a progression of senior finance roles with growth and performance-driven enterprises, from startup technology and Internet companies to small service providers ($50 million) to very large international manufacturers ($25 billion) to global banks.

Peter has advised and/or served as CFO in both publicly held and privately owned businesses since 1978. These include startup venture-capital-backed entrepreneurial companies; manufacturing, technology and service companies; and corporate and international banking. Other roles included human resources (HR) and Information Technology (IT) functions along with raising more than $500 million in debt and equity for his companies and their customers.

About TNI BioTech, Inc.

TNI BioTech, Inc., is a biotech company working to combat chronic, life-threatening diseases through the activation modulating the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical program involves immunotherapy with Methionine Enkephalin (MENK) and or Opioid Growth Factor (OGF, which has been shown to stimulate the immune system even in patients with advanced cancer.)

However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for low dose naltrexone and/or MENK as valuable candidates in the treatment of the following: 

  • Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
  • As an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery;
  • As an adjunct to antibiotics in the treatment of a variety of infectious diseases, including:
  • Patients with AIDS, in combination with retroviral drug therapy

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See for more information.
Contact: Global Investment Media
Phone:  310-353-6277

SOURCE TNI BioTech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
2. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
3. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
6. BioDelivery Sciences Announces Completion of BNX Safety Study
7. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
8. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
9. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
10. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
11. Healthy Mother Announces Certified Lamaze Childbirth Educator Workshop
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):